Can you work with proprietary or unstable antigens?

Yes. We have extensive experience with challenging antigens. We offer antigen stabilization services and can utilize specialized panning techniques (e.g., "subtractive panning") to focus on specific epitopes.

Do I own the Intellectual Property (IP) of the discovered antibodies?

Absolutely. Creative Biolabs operates on a fee-for-service basis. All sequences, data, and materials generated during the project are the sole property of the client.

Why is phage display better than hybridoma for horse antibodies?

Equine hybridoma technology is notoriously difficult because horse myelomas are not readily available, and inter-species fusions (horse-mouse) are often genetically unstable, leading to the loss of antibody production over time. Phage display bypasses these biological hurdles entirely.

What quantity of antigen is required?

Generally, we require 2-5 mg of high-purity antigen for the full process (immunization and screening). However, this can vary depending on the nature of the target.

Advanced Horse Monoclonal Antibody Discovery Service

Background Platform Workflow Specialized Service Advantage Related Services FAQ Online Inquiry

In the rapidly evolving landscape of biopharmaceuticals and veterinary medicine, the demand for high-affinity, high-specificity Horse Monoclonal Antibodies has reached unprecedented heights. As a global leader in antibody engineering with over two decades of experience, Creative Biolabs provides a comprehensive, end-to-end Horse Monoclonal Antibody Discovery platform. By leveraging our proprietary phage display-based Horse Monoclonal Antibody generation technology, we assist researchers in overcoming the traditional limitations of hybridoma technology, offering a robust pathway to discovering novel equine therapeutic and diagnostic leads.

Discuss Your Project Today

The Significance of Horse Monoclonal Antibody Discovery

Horses (Equus caballus) possess a sophisticated immune system capable of generating a diverse repertoire of antibodies. Unlike rodents, the equine immune system produces seven different IgG subclasses (IgG1 through IgG7), each with unique effector functions and structural characteristics. This complexity makes Horse Monoclonal Antibody discovery particularly valuable for:

Veterinary Therapeutics: Treating equine-specific diseases such as Equine Infectious Anemia (EIA), West Nile Virus, and various inflammatory conditions.
Passive Immunization: Utilizing horse-derived antibodies for anti-venom and anti-toxin treatments in humans and other animals.
Diagnostic Development: High-precision tools for detecting equine pathogens or physiological markers.
Cross-Species Research: Understanding the comparative immunology of large mammals.

Fig. 1 Horse. (Creative Biolabs Authorized)

State-of-the-Art Phage Display Platform for Equine Antibodies

At Creative Biolabs, our flagship approach is the Horse Monoclonal Antibody Discovery by phage display. While traditional hybridoma methods often struggle with low fusion efficiency in equine species and the instability of horse-mouse heterohybridomas, phage display offers a high-throughput, recombinant alternative that ensures the recovery of the full immune repertoire.

The Power of Phage Display-Based Horse Monoclonal Antibody Generation

Phage display involves the physical linking of a polypeptide (the antibody fragment) and the genetic information encoding it within a bacteriophage particle. This allows for the rapid screening of billions of variants to identify those with the highest affinity for a target antigen. Our platform is specifically optimized for the construction and screening of immune antibody libraries derived from immunized horses.

Key Advantages of Our Phage Display Platform

Vast Diversity: We can generate libraries with a diversity exceeding 10⁹ unique clones.
Animal-Free Selection: Once the library is constructed, the screening process (panning) is performed in vitro, allowing for strict control over selection conditions (pH, salt concentration, temperature).
Direct Gene Access: The DNA sequence of the selected Horse Monoclonal Antibody is immediately available for downstream recombinant expression and engineering.
Overcoming Self-Tolerance: Ability to isolate antibodies against highly conserved antigens that might be difficult to obtain via traditional immunization.

Comprehensive Workflow: Construction and Screening of Immune Antibody Library

Our Horse Monoclonal Antibody Discovery Service follows a rigorous, milestone-driven process designed to maximize success rates and affinity.

1. Antigen Design and Horse Immunization

The process begins with the design of a high-purity antigen. We work closely with clients to determine the best immunization strategy, utilizing proprietary adjuvants to elicit a strong humoral immune response in healthy donor horses.

2. B-Cell Isolation and RNA Extraction

Following the peak immune response, peripheral blood mononuclear cells (PBMCs) or lymphoid tissues are harvested. We perform meticulous total RNA extraction, ensuring the integrity of the antibody-coding sequences.

3. Immune Antibody Library Construction

This is a critical phase where our expertise shines. We utilize a specialized set of primers designed to amplify the full spectrum of equine V-heavy (VH) and V-light (VL) chains.

Library Formats: We typically offer scFv (single-chain variable fragment) or Fab (antigen-binding fragment) formats.
Construction Process: The amplified VH and VL repertoires are cloned into our high-efficiency phagemid vectors. This creates a massive immune antibody library for Horse Monoclonal Antibody discovery.

4. Biopanning and High-Throughput Screening

The immune antibody library is subjected to multiple rounds of "panning" against the target antigen.

Selection Strategies: Solid-phase panning (immunotubes/plates), solution-phase panning (magnetic beads), or cell-based panning for membrane proteins.
Enrichment Monitoring: We use polyclonal ELISA to monitor the enrichment of antigen-specific phages after each round.

5. Clone Characterization and Validation

Individual clones are selected and validated via:

Monoclonal ELISA: To confirm binding specificity.
Sequence Analysis: To identify unique CDR (Complementarity-Determining Region) patterns.
Affinity Measurement: Utilizing SPR (Surface Plasmon Resonance) or BLI (Bio-Layer Interferometry).

Specialized Immune Antibody Library Services

Creative Biolabs doesn't just offer a standard service; we provide specialized immune antibody library solutions tailored to the unique requirements of the equine system.

Construction of Large-Capacity Immune Libraries

The depth of an immune antibody library for Horse Monoclonal Antibody is the primary determinant of finding a "rare" high-affinity binder. We use optimized PCR protocols to minimize sequence bias and maximize the representation of the horse's natural immune response.

Screening Strategies for Complex Targets

Whether your target is a small molecule (hapten), a complex multi-pass transmembrane protein (GPCR), or a carbohydrate, our screening strategies are adapted to maintain the native conformation of the antigen, ensuring the resulting Horse Monoclonal Antibody is functional in real-world applications.

Why Choose Creative Biolabs for Horse Monoclonal Antibody Discovery?

As a pioneer in the field, our reputation is built on technical excellence and a deep understanding of equine immunology.

20+ Years of Expertise: We have successfully completed thousands of antibody discovery projects across various species.
Proprietary Primer Sets: Our equine-specific primers cover all known V-gene families, ensuring no potential lead is left behind.
Advanced Bioinformatics: We employ NGS (Next-Generation Sequencing) to analyze library diversity and track enrichment during panning, providing a data-driven approach to clone selection.
Scalable Production: Once a lead is identified, we offer large-scale recombinant production in mammalian systems (e.g., CHO, HEK293) to provide gram-level quantities of your Horse Monoclonal Antibody.

At Creative Biolabs, we are committed to pushing the boundaries of what is possible in Horse Monoclonal Antibody Discovery. Our integration of traditional immunology with cutting-edge phage display and immune antibody library technology ensures that our clients receive leads of the highest quality. Whether you are developing the next generation of equine therapeutics or a life-saving anti-toxin, our team of experts is ready to collaborate with you.

Explore Our Comprehensive Services

While our phage display immune antibody library platform is a powerful engine, we offer a comprehensive suite of discovery technologies to ensure we always use the right tool for the job. Our Monoclonal Antibody Generation from Various Immunized Antibody Libraries Services:

Contact us today to discuss your project requirements and discover how our phage display-based Horse Monoclonal Antibody platform can accelerate your research goals.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Can you work with proprietary or unstable antigens?
A: Yes. We have extensive experience with challenging antigens. We offer antigen stabilization services and can utilize specialized panning techniques (e.g., "subtractive panning") to focus on specific epitopes.
Q: Do I own the Intellectual Property (IP) of the discovered antibodies?
A: Absolutely. Creative Biolabs operates on a fee-for-service basis. All sequences, data, and materials generated during the project are the sole property of the client.
Q: Why is phage display better than hybridoma for horse antibodies?
A: Equine hybridoma technology is notoriously difficult because horse myelomas are not readily available, and inter-species fusions (horse-mouse) are often genetically unstable, leading to the loss of antibody production over time. Phage display bypasses these biological hurdles entirely.
Q: What quantity of antigen is required?
A: Generally, we require 2-5 mg of high-purity antigen for the full process (immunization and screening). However, this can vary depending on the nature of the target.

Reference

Wibmer, Constantinos Kurt, and Poppy Mashilo. "Exploiting V-Gene bias for rapid, High-Throughput monoclonal antibody isolation from horses." Viruses 14.10 (2022): 2172. https://doi.org/10.3390/v14102172

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.